← Back to home

Refractory acute myeloid leukemia due to lineage switch from B acute lymphoblastic leukemia, KMT2A-rearranged

Clinical trials for Refractory acute myeloid leukemia due to lineage switch from B acute lymphoblastic leukemia, KMT2A-rearranged explained in plain language.

Never miss a new study

Get alerted when new Refractory acute myeloid leukemia due to lineage switch from B acute lymphoblastic leukemia, KMT2A-rearranged trials appear

Sign up with your email to follow new studies for Refractory acute myeloid leukemia due to lineage switch from B acute lymphoblastic leukemia, KMT2A-rearranged, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Promising new combo targets Hard-to-Treat infant leukemia

Disease control Ongoing

This study tests a new oral drug (revumenib) combined with standard chemotherapy for infants and young children with a specific type of leukemia (KMT2A-rearranged) that has returned or not responded to treatment. The goal is to see if the combination is safe and works better than…

Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA DUE TO LINEAGE SWITCH FROM B ACUTE LYMPHOBLASTIC LEUKEMIA, KMT2A-REARRANGED

Phase 2 • Sponsor: Children's Oncology Group • Aim: Disease control

Last updated Aug 27, 2026 00:00 UTC

Refractory acute myeloid leukemia due to lineage switch from B acute lymphoblastic leukemia, KMT2A-rearranged

Get alerted when new Refractory acute myeloid leukemia due to lineage switch from B acute lymphoblastic leukemia, KMT2A-rearranged trials appear

Promising new combo targets Hard-to-Treat infant leukemia